Leadership Changes and Strategic Questions
Investors are also watching closely to see whether Novo’s leadership shake-up leads to meaningful improvements in its U.S. operations. The company replaced its long-serving chief executive last year, followed by the resignation of several independent board members amid disagreements over strategy and pace of change.
“The U.S. market is a show-me case for Novo right now,” Hansen said. “This is a must-win battle for the company’s leadership.”
Further uncertainty lies ahead as Novo navigates patent expirations in several international markets and prepares data readouts for next-generation treatments such as CagriSema, a combination therapy aimed at improving long-term weight management.
Despite these headwinds, analysts say the Wegovy pill approval carries symbolic weight.
“This was a company that needed a win,” Andersen said. “Now the challenge is execution.”
